Back
Can YouTuber Be Gagged Over Product Review? Lifts Injunction on Arpit Mangal
The has delivered a significant ruling for free speech and consumer advocacy, setting aside an that restrained YouTuber Arpit Mangal from publishing critical statements about Emami's "Zandu Ashwagandha Gold Plus" ayurvedic formulation. In a judgment that reaffirms the strict standards for , the Division Bench of Justice Sabyasachi Bhattacharyya and Justice Sandip Kumar De held that Mangal's had sufficient substance to survive the threshold required for an .
The case arose from a video uploaded on Mangal's popular "Trustified" channel on . In the video, Mangal presented laboratory test results that allegedly showed the product's Withanolide levels were below expected standards, while lead and mercury concentrations exceeded the limits prescribed under the . Emami swiftly moved the , which passed an on , barring Mangal from airing the video or making any statement about the product in any media. Mangal appealed, and the High Court's decision now paves the way for the video to be republished pending the final outcome of the suit.
Background: The Video and the Labs
Mangal's defence rested on the credibility of the testing process. He argued that the laboratory analyses were conducted by accredited institutions—specifically, , which the judgment notes is an -notified, and -accredited laboratory. Mangal also claimed that he had given Emami a 24-hour notice to respond before publishing the results, a practice he maintained to ensure fairness.
On the other hand, Emami relied on the product's Ayurvedic drug licence and contended that the detected lead and mercury were not contaminants but residues of Swarna Bhasma and Yashad Bhasma—ingredients intentionally added as part of the ayurvedic formulation. The company argued that these bhasmas are therapeutic in nature and that their heavy metal content is permissible under the API for herbo-metallic preparations.
The Court's Analysis: Categories and Standards
The High Court undertook a detailed examination of how the product should be classified under the API. It held that "Zandu Ashwagandha Gold Plus" could fall into three categories: an ayurvedic proprietary medicine, a herbo-metallic preparation, or a general formulation. Crucially, the court ruled that the product must satisfy the lowest permissible heavy-metal limits applicable to any of these categories—a standard that the laboratory reports suggested was breached.
The bench noted a critical gap in Emami's evidence: the company's expert reports did not dispute the actual quantities of lead and mercury found by Mangal's laboratories. Instead, they sought to explain the presence of these heavy metals as residues of Swarna Bhasma and Yashad Bhasma. However, the court observed that the expert opinions did not establish whether these ingredients neutralized the harmful effects of excessive lead and mercury. This lack of empirical evidence undermined Emami's defence and lent weight to Mangal's position that the product posed a potential health risk.
The Applied
The judgment is particularly notable for its robust application of the , a well-established common law doctrine that cautions courts against granting interim injunctions to restrain defamatory speech before trial. The principle holds that such relief should only be granted in exceptional cases where the defendant's or would "undoubtedly fail" at trial. The found that Mangal's was far from hopeless; indeed, it had "sufficient substance" to survive the preliminary stage.
The bench also considered the tone and context of the video. Emami had objected to phrases like "Poison in a bottle" and "Cancerous." The court, however, noted that the phrase "Poison in a bottle" was followed by question marks, indicating that it was framed as an inquiry rather than a definitive assertion. Similarly, the word "Cancerous" was used in proper context to alert consumers about the carcinogenic risk associated with excessive lead and mercury—a risk that the court found was not adequately rebutted by Emami's experts. The video, the bench observed, appeared more motivated by a desire to educate the public than by any commercial interest.
Implications for Free Speech and Consumer Advocacy
This ruling carries significant implications for content creators, journalists, and consumer advocacy groups. The High Court has sent a clear signal that corporations cannot easily silence critical product reviews through ex parte injunctions, especially when the reviewer has relied on accredited laboratory testing and has given the manufacturer an opportunity to respond. The decision reinforces the constitutional value of free speech and the public's right to know about potential health hazards.
For legal practitioners, the judgment provides a nuanced application of the in the context of online product reviews. It underscores the need for trial courts to scrutinize the strength of the defendant's defence before granting interim relief, and it warns against issuing gag orders that could stifle legitimate public debate. The court's insistence on empirical evidence—rather than mere explanations—to counter allegations of harmful heavy metal content sets a high bar for plaintiffs in product disparagement suits.
A Tentative But Impactful Order
The High Court was careful to clarify that its observations were tentative and should not influence the trial court at later stages of the suit. However, by lifting the injunction, the court has effectively allowed Mangal's video to remain in the public domain while the full trial proceeds. The bench also refused Emami's request to its judgment, observing that a would effectively revive the —a result the court was unwilling to countenance.
In a broader sense, the decision reflects a growing judicial awareness of the power of digital platforms and the need to balance commercial reputation with the public interest. As the line between product criticism and defamation becomes increasingly contested, the 's ruling offers a principled framework for evaluating prior restraints on speech.
Conclusion
The 's decision in is a landmark for those who believe that scientific scrutiny and public education should not be chilled by corporate litigation. By applying the with rigour, the court has ensured that the truth—however uncomfortable—can be spoken without fear of an immediate . For Arpit Mangal, it is a vindication of his right to question product safety. For the legal community, it is a reminder that the threshold for restraining speech remains high, and that courts must be vigilant guardians of free expression even in the face of powerful commercial interests.
